{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-021148","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.562521+00:00","generated_at":"2026-06-25T06:03:38.341194+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Brooklyn ImmunoTherapeutics appoints interim CEO Matt Angel, CFO Andrew Jackson; CEO Federoff resigns","bullets":["CEO Howard Federoff resigned effective May 26, 2022; received $225K bonus, $450K salary continuation, and accelerated stock options covering 1,420,095 shares.","Matt Angel, co-founder of Factor Bioscience, appointed interim President and CEO; Factor was a Novellus acquisition counterparty that received $1.7M cash and ~2.58M shares.","Andrew Jackson named CFO; receives $415K base salary, 40% target bonus, and a stock option grant for 664,800 shares.","Four directors (Heather Redman, Erich Mohr, Erin Enright, Dennis Langer) will not stand for reelection at postponed annual meeting.","2022 annual meeting postponed to a later date; new proxy statement expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-021148","json":"https://secwatch.observer/filing/0001140361-22-021148.json","markdown":"https://secwatch.observer/filing/0001140361-22-021148.md","text":"https://secwatch.observer/filing/0001140361-22-021148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/brhc10038309_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T06:03:38.341194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"584792d6e5","claim":"Matthew Angel was appointed as interim President and Chief Executive Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cfde03ff57","claim":"Howard J. Federoff, M.D., Ph.D. resigned as Chief Executive Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f928d0e6e1","claim":"Andrew Jackson was appointed as Chief Financial Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"On May 9 , 2022, the Board appointed Andrew Jackson as the Chief Finan","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}